OncoMatch/Clinical Trials/NCT06189209

Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)

Is NCT06189209 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Tenalisib for triple negative breast cancer (tnbc).

Phase 2RecruitingRhizen Pharmaceuticals SANCT06189209Data as of May 2026

Treatment: Tenalisib — This is a Phase II, open-label, single-arm, study, designed to evaluate the efficacy and safety of tenalisib in patients with metastatic TNBC, who have received at least one but not more than 3 prior therapies in a metastatic setting.

Check if I qualify

Extracted eligibility criteria

Cancer type

Triple-Negative Breast Cancer

Breast Carcinoma

Disease stage

Metastatic disease required

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Max 3 prior lines

Min 1 prior line

Cannot have received: pi3k inhibitor (alpelisib, buparlisib)

Lab requirements

Blood counts

adequate bone marrow function

Kidney function

adequate renal function

Liver function

adequate liver function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify